期刊文献+

多药耐药基因和脂蛋白酯酶基因多态性对阿托伐他汀治疗缺血性脑卒中疗效的影响 被引量:6

下载PDF
导出
摘要 目的探讨多药耐药基因(MDR)-1 C3435T与脂蛋白酯酶基因(LPL)HindⅢ基因多态性对阿托伐他汀治疗缺血性脑卒中疗效的影响。方法缺血性脑卒中患者102例,给予阿托伐他汀治疗6个月。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对MDR-1 C3435T和LPL HindⅢ进行分型,观察不同基因型的治疗效果,对阿托伐他汀的应答时间及不同基因型之间的交互作用。结果①阿托伐他汀治疗后患者血清胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)均值较治疗前有所降低(P<0.05)。②MDR-1 C3435T不同基因型患者对阿托伐他汀的应答具有显著性差异,T/T型阿托伐他汀抵抗显著高于其他两种基因型(χ2=21.88,P<0.01)。LPL HindⅢ不同基因型对阿托伐他汀应答率也具有统计学差异,其中LPL HindⅢ+/+型基因型阿托伐他汀抵抗显著高于LPL HindⅢ-/-型(χ2=5.83,P<0.05)。MDR-1 C3435T和LPL HindⅢ的不同基因表型患者对阿托伐他丁应答时间无显著性差异。③MDR-1 C3435T T/T型和LPL HindⅢ+/+型之间未发现交互作用(P=0.146)。HDL与LDL水平与阿托伐他丁抵抗相关。结论 MDR-1 C3435T T/T型和LPL HindⅢ+/+型导致阿托伐他汀抵抗,可能会对阿托伐他汀在缺血性脑卒中的治疗效果产生负性影响。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2013年第24期6094-6097,共4页 Chinese Journal of Gerontology
基金 恩施市医药卫生科技计划项目(No.2011Z012)
  • 相关文献

参考文献13

  • 1苏晓广.阿托伐他汀的药理作用及临床应用分析[J].中国当代医药,2011,18(27):14-15. 被引量:30
  • 2Haramaki N, Ikeda H. Stain for heart failure:a potential for new treatment [ J]. Cardiovasc Res,2003 ;60:217-9.
  • 3各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33020
  • 4Della-Morte D, Moussa I, Elkind MS, et al. The short-term effect of atorv- astatin on carotid plaque morphology assessed by computer-assisted gray- scale densitometry : a pilot study[ J]. Neurol Res ,2011 ;33:991-4.
  • 5Voora D, Shah SH, Reed CR, et al. Pharmacogenetic predictors of stain- mediated low-density lipoprotein cholesterol reduction and dose response [ J]. Circ Cardiovase Genet ,2008 ; 1 : 100-6.
  • 6Palmeira A, Sousa E, Vasconeelos H, et aL Structure and ligand-based design of P-glyeoprotein inhibitors: a historical perspective [ J ].Curr Pharm Des,2012:22.
  • 7黄凤楼,刁孟元,俞云峰,张斌.Mdr1基因的C3435T多态性及其临床意义[J].海军医学杂志,2010,31(1):88-90. 被引量:2
  • 8Mega JL, Morrow DA, Brown A, et al. Identification of genetic variants as- sociated with response to statin therapy[J]. Arteioscler Thromb Vasc Bi- ol,2009 ;29 : 1310-5.
  • 9Nakamura T. MDR1 genetype related to pharmacokinetics and MDR1 ex- pression[ J]. Yakugaku Zasshi ,2003 ; 123:773-9.
  • 10Munshi A, Babu MS, Kaul S,et al. Association of LPL gene variant and LDL, HDL, VLDL cholesterol and triglyceride levels with ischemic stroke and its subtypes [ J }. J Neurol Sci, 2012 ; 15 ; 318:51 4.

二级参考文献22

  • 1施明,张学国.辛伐他汀治疗高脂血症患者的疗效观察[J].华西医学,2008,23(5). 被引量:18
  • 2V Annese,MR Valvano,O Palmieri,A Latiano,F Bossa,A Andriulli.Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis[J].World Journal of Gastroenterology,2006,12(23):3636-3644. 被引量:14
  • 3Sotiriou GG,Cheng JW.Benificial effects of starins in coronary artery disease-beyond lowering cholesterol[J].Ann-Parmacothor,2009,34(12):1432-1439.
  • 4Sotiriou GG,Cheng JW.Benificial effects of starins in coronary artery disease-beyond lowering cholesterol[J].Ann-Parmacothor,2009.34(12):1432-1439.
  • 5Williams JK,Sukhva GK,Tterrington DM,et al.Pravastatin has Cholesterol lowering independent effects on the artery wall of adleroscle rotic monkeys[J].J Am coll Cardiol,2008,31(2):684-691.
  • 6Ahn YI, Kamboh RF, Hamman SA, et al. Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease[J]. J Lipid Res, 1993, 34(3): 421-428.
  • 7Chamberlain JC, Thorn JA,Oka K, et al. DNA polymorphisms at the lipoprotein lipase gene: associations in normal and hypertriglyceridaemic subjects [J].Atherosclerosis. 1989, 79:85-91.
  • 8Chan LY, Lan CW, Mak YT, et al. Genotype-phenotype studies of six novel LPL mutations in Chinese patients with hypertriglyceridemia genetic basis of hypertriglyceridemia [J]. Hum Mutat, 2002, 20:232-233.
  • 9Colwell JA.Multifactorial aspects of treatment of the type 2 diabetic patients [J]. Metabolism, 1997, 46(Supple 1):1-4.
  • 10Lasko M, Lehto S, Penttila I, et al. Lipids and lipoprotein predicting coronary heart disease mortality and morbidity in patients with ono-insulin-dependent diabetes [J].Circulation, 1993, 88(4Ptl): 1 421-1 430.

共引文献33056

同被引文献54

引证文献6

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部